{"id":3501,"date":"2023-02-14T08:56:16","date_gmt":"2023-02-13T21:56:16","guid":{"rendered":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/labelling-of-cannabidiol-cbd-products-a-public-health-perspective\/"},"modified":"2025-11-12T21:00:29","modified_gmt":"2025-11-12T10:00:29","slug":"labelling-of-cannabidiol-cbd-products-a-public-health-perspective","status":"publish","type":"post","link":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/labelling-of-cannabidiol-cbd-products-a-public-health-perspective\/","title":{"rendered":"Labelling of Cannabidiol (CBD) Products: A Public Health Perspective"},"content":{"rendered":"

Conclusions:<\/b> Accurate and informative labelling of hemp and hemp-derived CBD products is an important public health issue. FDA-regulated product labels are considered an essential tool for protecting consumers and enabling informed decision-making. Untruthful or unsubstantiated health-related claims, and unallowed Drug Claims, in marketing materials and on labels of CBD products may create harm by enticing consumers to forgo more evidence-based medical interventions. Furthermore, missing or inaccurate labelling of the amount of CBD, delta-9 tetrahydrocannabinol (THC), and potentially harmful contaminants such as pesticides, naturally-occurring yeast and mold or heavy metals may result in harm and\/or lack of efficacy. Manufacturers of these products may reasonably be expected to understand and adhere to FDA regulations for labelling and marketing of food, dietary supplements and drugs, both over-the-counter (OTC) and prescription, even though FDA has interpreted federal law as excluding them from these categories. As manufacturers prepare for forthcoming regulations, a better understanding of the basic framework for FDA labelling and marketing regulations for food, dietary supplements and drugs is warranted.
<\/span><\/p>\n

For Full Research <\/a>
<\/span><\/p>\n

Also see
<\/span><\/p>\n